Q1 Earnings Estimate for Inozyme Pharma Issued By Wedbush

Inozyme Pharma, Inc. (NASDAQ:INZY) – Analysts at Wedbush issued their Q1 2025 earnings per share (EPS) estimates for Inozyme Pharma in a report issued on Monday, March 10th. Wedbush analyst D. Nierengarten anticipates that the company will post earnings of ($0.43) per share for the quarter. Wedbush has a “Outperform” rating and a $7.00 price target on the stock. The consensus estimate for Inozyme Pharma’s current full-year earnings is ($1.59) per share. Wedbush also issued estimates for Inozyme Pharma’s Q2 2025 earnings at ($0.25) EPS, Q3 2025 earnings at ($0.25) EPS, Q4 2025 earnings at ($0.25) EPS, FY2025 earnings at ($1.15) EPS, FY2026 earnings at ($1.01) EPS and FY2027 earnings at ($0.80) EPS.

Several other equities analysts have also commented on the company. Piper Sandler lowered their target price on Inozyme Pharma from $30.00 to $23.00 and set an “overweight” rating for the company in a report on Tuesday. HC Wainwright reissued a “buy” rating and issued a $16.00 price objective on shares of Inozyme Pharma in a report on Tuesday. Wells Fargo & Company decreased their price objective on Inozyme Pharma from $14.00 to $11.00 and set an “overweight” rating for the company in a report on Monday, January 13th. Raymond James cut their target price on Inozyme Pharma from $24.00 to $12.00 and set an “outperform” rating for the company in a research report on Wednesday. Finally, Needham & Company LLC cut their target price on Inozyme Pharma from $23.00 to $15.00 and set a “buy” rating for the company in a research report on Tuesday. Nine analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Inozyme Pharma has a consensus rating of “Buy” and an average price target of $14.56.

Inozyme Pharma Stock Up 1.9 %

NASDAQ:INZY opened at $1.08 on Thursday. The firm has a market capitalization of $69.38 million, a PE ratio of -0.69 and a beta of 1.32. The stock has a 50 day moving average of $1.52 and a 200-day moving average of $3.28. Inozyme Pharma has a 52 week low of $0.98 and a 52 week high of $7.80. The company has a current ratio of 7.68, a quick ratio of 7.68 and a debt-to-equity ratio of 0.51.

Institutional Investors Weigh In On Inozyme Pharma

Institutional investors and hedge funds have recently modified their holdings of the stock. abrdn plc acquired a new stake in shares of Inozyme Pharma during the 4th quarter valued at $472,000. Eventide Asset Management LLC lifted its position in shares of Inozyme Pharma by 5.0% during the 3rd quarter. Eventide Asset Management LLC now owns 4,134,436 shares of the company’s stock valued at $21,623,000 after acquiring an additional 198,216 shares during the last quarter. Barclays PLC raised its stake in Inozyme Pharma by 261.4% during the 3rd quarter. Barclays PLC now owns 76,730 shares of the company’s stock valued at $401,000 after purchasing an additional 55,497 shares during the period. Geode Capital Management LLC raised its stake in Inozyme Pharma by 1.7% during the 3rd quarter. Geode Capital Management LLC now owns 1,171,172 shares of the company’s stock valued at $6,126,000 after purchasing an additional 19,499 shares during the period. Finally, State Street Corp raised its stake in Inozyme Pharma by 5.0% during the 3rd quarter. State Street Corp now owns 1,050,420 shares of the company’s stock valued at $5,494,000 after purchasing an additional 50,386 shares during the period. Institutional investors and hedge funds own 88.30% of the company’s stock.

Inozyme Pharma Company Profile

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.